DexCom, Inc. is an American healthcare company that develops, manufactures, produces, and distributes a line of

continuous glucose monitor A continuous glucose monitor (CGM) is a device for monitoring blood glucose continuously instead of monitoring periodically by drawing a drop of blood from a finger. This is known as continuous glucose monitoring. CGMs are used by people who trea ...

ing (CGM) systems for

diabetes Diabetes mellitus, commonly known as diabetes, is a group of common endocrine diseases characterized by sustained high blood sugar levels. Diabetes is due to either the pancreas not producing enough of the hormone insulin, or the cells of th ...

management. It operates internationally with headquarters in

San Diego San Diego ( , ) is a city on the Pacific coast of Southern California, adjacent to the Mexico–United States border. With a population of over 1.4 million, it is the List of United States cities by population, eighth-most populous city in t ...

, California; and has manufacturing facilities in

Mesa, Arizona Mesa ( ) is a city in Maricopa County, Arizona, United States. The population was 504,258 at the 2020 census. It is the List of municipalities in Arizona, third-most populous city in Arizona, after Phoenix, Arizona, Phoenix and Tucson, Arizona, T ...

; Batu Kawan, Malaysia; and

Athenry Athenry (; ) is a town in County Galway, Ireland, which lies east of Galway city. Some of the attractions of the medieval town are its town wall, Athenry Castle, its priory and its 13th-century street-plan. The town is also well known by virt ...

, Ireland.

History

Dexcom was founded in 1999 by Scott Glenn, John Burd, Lauren Otsuki, Ellen Preston and Bret Megargel. In 2006, Dexcom received U.S.

Food and Drug Administration The United States Food and Drug Administration (FDA or US FDA) is a List of United States federal agencies, federal agency of the United States Department of Health and Human Services, Department of Health and Human Services. The FDA is respo ...

(FDA) approval and launched the Dexcom STS Continuous Glucose Monitoring System, which is a three-day sensor that provides up to 288 glucose measurements for every 24 hours. Dexcom received approval of the second generation product, the Seven Continuous Glucose Monitoring System, in May 2007. This device improved on accuracy and extended use from three to seven days. In 2008, Dexcom announced two consumer development agreements with Insulet Corporation and Animas Corporation as well as a development agreement with

Edwards Lifesciences Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring. It developed the Sapien transcatheter aortic heart valve made of cow tissue w ...

for a continuous glucose monitor in the

intensive care unit An intensive care unit (ICU), also known as an intensive therapy unit or intensive treatment unit (ITU) or critical care unit (CCU), is a special department of a hospital or health care facility that provides intensive care medicine. An inten ...

hospital environment. During February 2009, Dexcom received approval for the Seven Plus Continuous Glucose Monitor, its new continuous glucose monitoring system, from the FDA. This product received a

CE mark The presence of the logo on Product (business), commercial products indicates that the Manufacturing, manufacturer or importer affirms the goods' conformity with European Environment, health and safety, health, safety, and environmental prote ...

in November 2009. In 2013, development work for integration with Insulet was discontinued. Dexcom entered a non-exclusive agreement with Tandem Diabetes Care, Inc. in 2015 to allow the integration of its forthcoming G5 and G6 continuous glucose monitoring systems into Tandem's insulin pumps. The G5 was approved in 2016 by the

FDA The United States Food and Drug Administration (FDA or US FDA) is a federal agency of the Department of Health and Human Services. The FDA is responsible for protecting and promoting public health through the control and supervision of food ...

for use as a standalone device, while the G6 gained approval in 2018. Dexcom's first G-series CGM, the G4 Platinum, received a CE mark and FDA approval in 2012 for adults ages 18 and over. This device improved hypoglycemic accuracy by 30%. It also offered a longer range of transmission between the sensor and receiver, as well as a color

LCD A liquid-crystal display (LCD) is a flat-panel display or other electronically modulated optical device that uses the light-modulating properties of liquid crystals combined with polarizers to display information. Liquid crystals do not em ...

. The G4 Platinum was approved by the FDA for use in patients ages 2–17 in February 2014. Dexcom received FDA approval in January 2015 for the G4 Platinum with Share, which enabled the sharing of CGM data with up to five other people using the "Share" and "Follow" smartphone apps. The Dexcom G5 was approved in August 2015 by the FDA for use as a standalone device, the G5 has

Bluetooth Bluetooth is a short-range wireless technology standard that is used for exchanging data between fixed and mobile devices over short distances and building personal area networks (PANs). In the most widely used mode, transmission power is li ...

integrated into its transmitter, enabling it to send data to a mobile device. This allows for use of the device without the standalone receiver. The Dexcom G5 received a CE mark in September 2015. Dexcom went public in 2005 and is listed on the

Nasdaq Global Select Market The Nasdaq Stock Market (; National Association of Securities Dealers Automated Quotations) is an American stock exchange based in New York City. It is the most active stock trading venue in the U.S. by volume, and ranked second on the list ...

stock exchange under the ticker symbol DXCM. On April 20, 2020, Dexcom became a component of the

Nasdaq-100 The Nasdaq-100 (NDX) is a stock market index made up of equity securities issued by 100 of the largest non-financial companies listed on the Nasdaq stock exchange. It is a modified capitalization-weighted index. The stocks' weights in the inde ...

, replacing

American Airlines Group American Airlines Group Inc. is an American publicly traded airline holding company headquartered in Fort Worth, Texas. It was formed on December 9, 2013, by the merger of AMR Corporation, the parent company of American Airlines, and US Airway ...

in the index. The Dexcom G7 was approved in December 2022 by the FDA for use as a standalone device and is the most accurate currently approved CGM in the U.S.

Awards and recognition

In October 2024, ''

Time Magazine ''Time'' (stylized in all caps as ''TIME'') is an American news magazine based in New York City. It was published weekly for nearly a century. Starting in March 2020, it transitioned to every other week. It was first published in New York Cit ...

'' named Dexcom Stelo's over-the-counter glucose monitor one of the year's best inventions.

Partnerships

* Dexcom entered into a partnership in 2015 with Google Life Sciences (which subsequently became

Verily Verily Life Sciences LLC, also known as Verily (formerly Google Life Sciences), is Alphabet Inc.'s research organization devoted to the study of life sciences. The organization was formerly a division of Google X, until August 10, 2015, when Ser ...

) to develop the Dexcom G7 * Dexcom entered a non-exclusive agreement with Tandem Diabetes Care, Inc. in 2015 to allow the integration of its new G5 and G6 continuous glucose monitoring systems into Tandem's insulin pumps. Tandem Diabetes Care received FDA approval in December 2019 for Control-IQ, a closed-loop technology that uses Tandem's t:slim X2 insulin pump and the Dexcom G6 "to automatically increase, decrease, or stop the delivery of insulin in response to the glucose levels of people with Type 1 diabetes." * In June 2019, Dexcom announced a collaboration with Companion Medical to enable the exchange of CGM data from Dexcom with insulin data from InPen into both companies' software applications. * Dexcom entered into a partnership with Livongo, a digital chronic care management company, in January 2020 to share CGM data from the Dexcom G6 with Livongo's platform. This integration allowed Livongo to incorporate the CGM data along with other patient data. * In February 2020, Dexcom and Insulet Corporation signed a non-exclusive, global agreement to combine current and future Dexcom continuous glucose monitoring systems with Insulet's tubeless insulin delivery Pod into the Omnipod Horizon System for automated insulin delivery. This allowed the ability to adjust insulin doses based on Insulet's algorithm or through their smartphone. * The company also announced in March 2020 a partnership with Welldoc to integrate G6 CGM data with BlueStar, a digital platform for diabetes management. * In November 2024, Dexcom announced a "strategic partnership" and data exchange with Oura.

Venture capital arm

In early 2021, Dexcom launched ''Dexcom Ventures'', a venture capital arm focused on emerging continuous glucose monitoring technologies and devices measuring the levels of other types of substances and analytes. In practice, Dexcom Ventures has also invested in cybersecurity platforms for the software used in medical devices.

References

External links